Global HMO Formula Market Research Report 2026

The global HMO Formula market was valued at US$ 4200 million in 2025 and is anticipated to reach US$ 8633 million by 2032, at a CAGR of 11.0% from 2026 to 2032.

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on HMO Formula competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

HMO (Human Milk Oligosaccharides) formula milk refers to a specialized type of infant formula that incorporates oligosaccharides found naturally in human breast milk. These oligosaccharides are complex carbohydrates that serve various beneficial purposes, particularly for the infant’s digestive system and immune health. Breast milk is known to contain more than 200 different types of oligosaccharides, which play an important role in the development of the infant's gut microbiota, immunity, and overall health. Since these oligosaccharides are difficult to replicate, HMO formula has emerged as a substitute that mimics the benefits of breast milk, offering an advanced alternative for infants who may not have access to breastfeeding.

The primary purpose of HMO formula is to offer infants essential nutrients and bioactive components similar to those in breast milk. This includes providing support for immune defense, digestive health, and overall growth. The introduction of HMOs in infant formulas has revolutionized the infant nutrition market, offering a more scientific approach to supplementing breast milk for mothers who cannot breastfeed or who require additional support for their infants’ nutrition.

HMO formula milk typically comes in a range of variations to cater to specific infant needs. This includes:

Standard HMO formula: Aimed at healthy, full-term infants, providing all-around nutrition for growth and development.

Preterm and low birth weight HMO formula: Designed for premature or low birth weight infants, ensuring that their sensitive digestive systems receive the necessary support for optimal health.

Sensitive stomach HMO formula: Made for babies experiencing digestive discomforts like colic or reflux, this formula may contain additional components like probiotics or easier-to-digest proteins.

HMO formula with additional probiotics or nutrients: To support not just gut health but also immune development, these formulas combine HMOs with other beneficial ingredients such as probiotics, prebiotics, or DHA (docosahexaenoic acid).

The product is available in various forms such as powder, ready-to-feed liquid, and concentrated liquid, allowing parents to choose based on convenience and preference.

The market for HMO formula milk has experienced rapid growth due to several key factors. The growing awareness among parents of the critical role HMOs play in infant health has been a driving force. With increasing understanding of the benefits of HMOs in mimicking the bioactive components of breast milk, there is a rising demand for infant formulas that incorporate these oligosaccharides. As breastfeeding rates decline in some parts of the world, especially in urban areas, the demand for high-quality alternatives such as HMO formula milk has surged.

Market Opportunities: The emerging markets in Asia, Latin America, and the Middle East present significant growth opportunities for companies offering HMO-based formula milk. With rising disposable incomes and increased awareness of the importance of infant nutrition, these regions are expected to witness substantial demand for premium formula products. Innovations in production technologies, such as fermentation processes to create HMOs more efficiently, are also expected to make HMO-based formula more cost-effective, driving wider adoption across different demographics. Additionally, as more regulatory authorities approve the inclusion of HMOs in infant formula, companies have more opportunities to expand into new regions.

Market Risks: One of the major risks in the HMO formula market is the high production cost. The extraction and synthesis of HMOs remain an expensive and complex process, which can increase the price of the formula and limit its accessibility in price-sensitive markets. Regulatory challenges can also pose risks, as the approval of HMO inclusion in infant formula is still subject to different guidelines across regions. Furthermore, competition among major players in the market, including Abbott, Nestlé, Danone, and Mead Johnson, can limit market entry for smaller players, making it challenging for new companies to compete on price and innovation.

Market Concentration: The market is currently highly concentrated, with a few key players dominating the industry. Global giants like Abbott, Nestlé, Danone, and FrieslandCampina hold significant market share, primarily due to their established brand presence and distribution networks. This concentration of power limits opportunities for new entrants, although the growing consumer demand for HMO-based formula may attract smaller players looking to target niche segments of the market. However, as the market grows and diversifies, there may be room for more players to carve out a place.

Downstream Demand Trends: As consumer awareness about the benefits of HMO formula milk continues to rise, especially in developed markets, the demand for these formulas is expected to grow. Parents are increasingly looking for infant nutrition options that offer both convenience and nutritional superiority over traditional formulas. As breastfeeding rates are lower in some regions, particularly in developed countries, more parents are turning to HMO-based formulas to ensure their babies receive the best possible start in life. There is also a rising trend in seeking organic and clean-label formulas, which is likely to benefit the HMO formula segment as it is often marketed as a more natural and science-backed alternative to traditional formula milk.

Latest Technologies: The use of biotechnology in HMO production has been a major advancement in the field of infant nutrition. Companies are leveraging fermentation-based techniques to produce HMOs more efficiently and cost-effectively. These advances have the potential to reduce the cost of HMO formula milk, making it more accessible to a broader market. Additionally, the incorporation of other beneficial ingredients, such as prebiotics, probiotics, and DHA, alongside HMOs, is gaining traction as part of the latest innovations in the industry. These ingredients work synergistically to support the infant’s immune system, digestive health, and overall development.

This report delivers a comprehensive overview of the global HMO Formula market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding HMO Formula. The HMO Formula market size, estimates, and forecasts are provided in terms of sales volume (K Tons) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global HMO Formula market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist HMO Formula manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.